Why Deep Discounts Make Indonesian Hospital Stocks a Convincing Buy Right Now

JAKARTA, Investortrust.id — A stark disconnect has emerged in the Indonesian healthcare sector, where robust fundamental earnings are colliding with a brutal sell-off in equity prices.

BRI Danareksa Sekuritas, a leading Indonesian institutional brokerage, reports that hospital operators are positioned to post stellar second-quarter earnings for 2026. However, current stock prices fail to reflect this operational strength, handing global investors a highly attractive entry point into Southeast Asia's premier healthcare market.

The aggressive decoupling of corporate earnings from stock valuations marks a classic value play in an emerging market. Foreign institutions have aggressively dumped Indonesian hospital equities this year, creating an artificial technical drag that has pushed valuations well below their historic five-year averages. With structural demand for private healthcare rising among Indonesia’s expanding middle class, this steep discount offers an asymmetric risk-reward profile for international capital.

Booming Patient Volumes Drive 19% Profit Surge

"We project the hospital sector's aggregate net profit to surge by approximately 19% year-on-year in the second quarter of 2026," stated Wilastita Muthia Sofi, an equity analyst at BRI Danareksa Sekuritas, in her latest research report published on Monday, July 13, 2026. "Our channel checks reveal that a higher number of operational working days during the quarter heavily supported healthcare services delivery."

The brokerage forecasts that patient volumes expanded 3% quarter-on-quarter and 5% year-on-year, while revenue intensity and operating margins held firm. By the close of the first half of 2026, the sector has already locked in 46% of its full-year earnings target, aligning perfectly with historical seasonal trends.

Inside the Big Three Operators

The operational execution across the country's top private healthcare networks remains highly disciplined. Industry giant PT Mitra Keluarga Karyasehat Tbk (MIKA) tracking at 45% of its full-year consensus, while PT Medikaloka Hermina Tbk (HEAL), the country's dominant mass-market hospital operator, hit 45% of internal targets. Meanwhile, PT Siloam International Hospitals Tbk (SILO), the premium healthcare arm of the Lippo conglomerate, outpaced expectations by reaching 47% of its full-year forecast.

These operators are aggressively squeezing out higher margins through distinct operational strategies. MIKA is successfully optimizing its mix by capturing high-complexity medical cases, while SILO expands its specialized doctor network through its tech-heavy "hospital of the future" initiative. Concurrently, HEAL is driving commercial monetization through strategic corporate partnerships and an asset-light operatorship model.

Prices Plummets Despite Solid Fundamentals

Despite this operational excellence, stock prices have tumbled across the board. Year-to-date market data reveals that MIKA has corrected 29%, SILO has dropped 21%, and HEAL has plummeted 34%. This fierce correction was severely exacerbated by international fund managers, who pulled Rp 516 billion ($32.45 million) out of the sector.

BRI Danareksa Sekuritas argues that this sell-off is completely unjustified, noting that enterprise value-to-EBITDA multiples for MIKA and HEAL are trading deep below their five-year historical averages. Consequently, the firm maintained its absolute Overweight rating on the sector, slapping a buy recommendation on all three stocks with target prices of Rp 3,300 for MIKA, Rp 2,850 for SILO, and Rp 1,550 for HEAL.

"MIKA remains our top pick because it boasts the most resilient earnings growth profile among its peers," Sofi wrote in the client note on Monday, July 13, 2026. "The company maintains a healthy profitability framework with a projected return on equity (ROE) of 19.8%, yet it trades at an incredibly attractive valuation of just 9.7 times EV/EBITDA."

However, analysts caution that global macro players must monitor minor headwinds, including sudden changes to the state-mandated BPJS national health insurance referral system, potential drops in patient intensity, or lower-than-expected admission volumes.